GVFL exits Axio Bio Solutions with 7-times returns

Retrieved on: 2018-02-01 18:20:49

Tags for this article:

Click the tags to see associated articles and topics

GVFL exits Axio Bio Solutions with 7-times returns. View article details on hiswai:

Excerpt

<div>Existing investors Accel Partners and <b>IDG Ventures</b> also participated in this round," a statement said here. Axio's flagship product Axiostat is a patented and CE approved haemostatic device. The company has multiple patents to its credit. Sanjay Randhar, Managing Director, GVFL Ltd, said, "GVFL could ...</div>

Article found on:

View Original Article